Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABAL.L Regulatory News (ABAL)

  • There is currently no data for ABAL

Share Option Schemes

15 Feb 2012 07:00

RNS Number : 4324X
Imaginatik PLC
15 February 2012
Β 

ο»Ώ

15 February 2012

Imaginatik plc

("Imaginatik" or the "Company")

Β 

Share Option Schemes

Β 

Imaginatik plc (AIM: IMTK), a leading provider of enterprise innovation services including a range of technology products and consultancy, announces that the remuneration committee of the Board has approved changes to the terms of the existing share options issued by the Company.

Β 

There are currently 27,461,845 options outstanding under the Company's various share option schemes, of which 24,012,500 are held by directors and eligible employees. 12,006,250 of these options have now been cancelled and the exercise price of a further 12,006,250 options, which currently ranges from 2.0p to 2.55p, has been rebased to 1p per share. The mid-market price of the Company's ordinary shares as at close of business on 14 February 2012 was 0.42p.

Β 

In addition, the Company has awarded 64,425,000 new share options to directors and employees with an exercise price of 1p per share ("New Options"):

Β 

a. Matt Cooper, Shawn Taylor, Luis Solis and Nicholas Goss, each being an executive director of the Company, have been granted 17,500,000, 11,125,000, 7,500,000 and 5,000,000 options respectively. The grant of a higher number of options to Mr Cooper and Mr Taylor is in recognition of salary sacrifices on their part during the half-year to 30 September 2011. The share options for Mr Cooper and Mr Taylor will be a combination of options issued under The Imaginatik plc Enterprise Management Incentive Scheme ("EMI scheme") as well as unapproved options. The share options for Mr Goss will all be issued under the EMI scheme. The share options for Mr Solis shall be issued under the Imaginatik 2006 Stock Option Plan.

Β 

b. David Gammon, Simon Charles and Brian Hays, non-executive directors of the Company, have each been granted 2,000,000 share options. The share options for Mr Gammon and Mr Charles shall be issued as unapproved options, and those for Mr Hays shall be issued under the Imaginatik 2006 Stock Option Plan.

Β 

c. Key employees of the Company have been granted 17,300,000 share options under the EMI scheme as well as the Imaginatik 2006 Stock Option Plan.

Β 

The re-based options and the New Options will vest as to 50% two years after grant and 50% three years after grant, subject to certain events as particularised in the scheme rules.

Β 

The remuneration committee considers that the grant of the New Options and the combined re-basing and cancellation of existing options provides the senior management team and employees of the Company with an appropriate and effective incentive for the future.

Β 

In addition to the above grants, Northland Capital Partners Limited has been granted 3,206,451 options over new ordinary shares exercisable at any time at 0.5p per share expiring on 13 February 2017 (in connection with the recent placing and open offer).

Β 

Imaginatik now has 78,087,046 share options in issue, representing approximately 15.22% of the current issued share capital and 13.21% of the fully diluted share capital.

Β 

Executive Directors

Options

Matt Cooper

19,062,500

Shawn Taylor

14,225,000

Luis Solis

9,500,000

Nicholas Goss

5,000,000

Non-Executive Directors

David Gammon

2,000,000

Simon Charles

2,000,000

Brian Hays

2,000,000

Employees

17,643,750

Ex-employees

3,449,345

Northland Capital Partners

3,206,451

Β 

Β 

Β 

Matt Cooper, Shawn Taylor and Luis Solis, Executive Directors of the Company and Mr Andrew Wainwright, a former Executive Director of the Company, are participating in the re-basing of the existing share options to the extent of an aggregate of 8,537,500 options. The re-basing of the share options is deemed to be a related party transaction under the AIM Rules for Companies. Nicholas Goss, Brian Hays and David Gammon, the independent directors of the Company for the purposes of the transaction, having consulted with the Company's Nominated Adviser, Northland Capital Partners Limited, consider that the terms of the re-basing of the existing share options are fair and reasonable so far as the shareholders of the Company are concerned.

Β 

Matt Cooper, Executive Chairman of Imaginatik, commented, "Following a comprehensive review of the Company's share option schemes, we are pleased to have put in place a revised share option structure that we believe properly incentivises our employees to build the Company in the long term."

Β 

For further information please contact:

Β 

Imaginatik plc

Tel: 020 7917 2975

Matt Cooper, Executive Chairman / Shawn Taylor, CFO

Northland Capital Partners Limited

Tel: 020 7796 8800

Gavin Burnell / Edward Hutton

Newgate Threadneedle

Tel: 020 7653 9850

Caroline Evans-Jones / Hilary Millar

Β 

About Imaginatik

Β 

Imaginatik provides Innovation and Idea management solutions comprised of consultancy, software and program management to deliver innovation outcomes to companies such as The Chubb Group of Insurance Companies, Boeing, Pfizer, Goodyear, Paccar, Kellogg and Cargill. Few companies possess the internal capability to consistently generate fresh ideas, identify those worth pursuing and reliably transform them into real, value-enhancing assets. This is Imaginatik's area of expertise.

Β 

Imaginatik is a public company whose shares are traded on the AIM market of the London Stock Exchange (LSE:IMTK.L) and a World Economic Forum Technology Pioneer with offices in Boston, MA, and London. In 2009, Imaginatik was named as one of the 500 fastest growing technology companies in the EMEA region by Deloitte. For more information, visit www.imaginatik.com.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
RDSLLFVTFRISLIF
Date   Source Headline
27th Nov 20137:00 amRNSHalf Yearly Report
24th Oct 20137:00 amRNSContract Win
10th Oct 201310:01 amRNSHolding(s) in Company
2nd Oct 20137:00 amRNSIssue of Equity
1st Oct 201310:03 amRNSTransaction in Own Shares/Director's Dealing
23rd Sep 20137:00 amRNSContract Win with Shell
18th Sep 20132:03 pmRNSResult of AGM
27th Aug 20131:50 pmRNSNotice of AGM
24th Jul 20137:00 amRNSFinal Results
8th Jul 20137:00 amRNSContract Win
1st Jul 20137:00 amRNSChange of Adviser
21st Jun 20137:00 amRNSBoard Changes
13th Jun 20137:00 amRNSConsultancy Update
31st May 20137:00 amRNSTotal Voting Rights
16th May 20131:03 pmRNSHolding(s) in Company
16th May 20137:00 amRNSHolding(s) in Company
13th May 201312:16 pmRNSResult of General Meeting
26th Apr 20134:52 pmRNSPublication of Circular
26th Apr 20137:00 amRNSProposed Placing
16th Apr 201312:20 pmRNSCapital Market Strategy Update
7th Feb 20132:25 pmRNSTrading Update
10th Dec 20127:00 amRNSContract Wins
22nd Nov 20127:00 amRNSShare Options
21st Nov 20127:00 amRNSHalf Yearly Report
25th Oct 20127:00 amRNSTrading Update
2nd Oct 20127:00 amRNSLitigation Conclusion
14th Sep 20121:02 pmRNSResult of AGM
14th Sep 20127:00 amRNSAGM Statement
23rd Aug 20127:00 amRNSNotice of AGM
4th Jul 201212:04 pmRNSHolding(s) in Company
2nd Jul 20122:22 pmRNSHolding(s) in Company
29th Jun 20123:30 pmRNSHolding(s) in Company
29th Jun 201212:12 pmRNSHolding(s) in Company
28th Jun 20121:36 pmRNSHolding(s) in Company
27th Jun 201211:20 amRNSResult of General Meeting
20th Jun 20121:41 pmRNSDirectorate Change
11th Jun 20128:30 amRNSDirector/PDMR Shareholding
11th Jun 20128:00 amRNSFinal Results
11th Jun 20128:00 amRNSProposed Placing
17th Apr 20127:00 amRNSContract Wins
17th Apr 20127:00 amRNSTrading Update
29th Feb 20127:00 amRNSContract with US Healthcare Services Provider
21st Feb 20121:45 pmRNSHolding(s) in Company
20th Feb 201212:54 pmRNSHolding(s) in Company
15th Feb 201212:16 pmRNSHolding(s) in Company
15th Feb 20127:00 amRNSShare Option Schemes
8th Feb 20127:00 amRNSIssue of Equity
3rd Feb 201211:39 amRNSHolding(s) in Company
2nd Feb 201210:49 amRNSHolding(s) in Company
30th Jan 20127:00 amRNSSenior Management Appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.